Azilect News and Research

RSS
Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Study finds link between extended use MAO-B inhibitors and slow clinical decline in PD patients

Study finds link between extended use MAO-B inhibitors and slow clinical decline in PD patients

Teva to present abstracts on AZILECT at MDS meeting

Teva to present abstracts on AZILECT at MDS meeting

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva first quarter net revenues increase 25% to $5.1 billion

Teva first quarter net revenues increase 25% to $5.1 billion

Teva fourth quarter net revenues increase 28% to $5.7 billion

Teva fourth quarter net revenues increase 28% to $5.7 billion

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

Teva third quarter net sales increase 2% to $4.34 billion

Teva third quarter net sales increase 2% to $4.34 billion

Teva second quarter net sales increase 11% to $4.2 billion

Teva second quarter net sales increase 11% to $4.2 billion

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva fourth quarter net sales increase 16% to record $4.4 billion

Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

Teva third quarter net sales increase 20% to $4.3 billion

Teva third quarter net sales increase 20% to $4.3 billion

Watson seeks FDA approval to market rasagiline mesylate tablets

Watson seeks FDA approval to market rasagiline mesylate tablets

TEMPO study recommends early administration of Azilect in PD patients

TEMPO study recommends early administration of Azilect in PD patients

Teva second-quarter net sales increase 12% to $3.8 billion

Teva second-quarter net sales increase 12% to $3.8 billion

Study confirms Azilect as a selective MAO-B inhibitor

Study confirms Azilect as a selective MAO-B inhibitor

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting

Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.